Sequencing in Developed Urothelial Carcinoma

The indication for sacituzumab govitecan (Trodelvy) in previously handled sufferers with in the neighborhood evolved or metastatic urothelial most cancers was withdrawn splendid month after the drug failed to enhance survival versus single-agent chemotherapy in the section III TROPiCS-04 trial.

In gentle of this changed landscape, Joaquim Bellmunt, MD, PhD, of Dana-Farber Most cancers Institute in Boston, discusses second-line remedy alternatives.

Following is a transcript of his remarks:

Sequencing is now a reveal on anecdote of now we possess now, as mentioned, three alternatives for first-line remedy and the level is what to develop subsequent. And then in sufferers who’re receiving chemotherapy followed by maintenance avelumab [Bavencio], after that some sufferers are receiving enfortumab vedotin [EV, Padcev], after which after that receiving sacituzumab govitecan. That is the original sequencing on that.

In sufferers who’re receiving EV/[pembrolizumab (Keytruda)], then obviously the most logical subsequent step — and with out any data supporting that — we are giving cisplatin on anecdote of now we haven’t been the use of the cisplatin in first-line therapy.

Earlier than this ASCO [American Society of Clinical Oncology], one other thing that has not been offered is, we heard the press unencumber of the TROPiCS-04, that is the sacituzumab section III. Sadly, this trial was negative. And this is extremely concerning on anecdote of now we were going to possess one other drug, an ADC [antibody-drug conjugate] sacituzumab govitecan, for sequencing.